These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group. J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704 [Abstract] [Full Text] [Related]
6. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. Tanaseanu C, Milutinovic S, Calistru PI, Strausz J, Zolubas M, Chernyak V, Dartois N, Castaing N, Gandjini H, Cooper CA, 313 Study Group. BMC Pulm Med; 2009 Sep 09; 9():44. PubMed ID: 19740418 [Abstract] [Full Text] [Related]
7. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group. Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095 [Abstract] [Full Text] [Related]
8. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group. Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482 [Abstract] [Full Text] [Related]
12. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W. Curr Med Res Opin; 2008 Mar 15; 24(3):895-906. PubMed ID: 18419876 [Abstract] [Full Text] [Related]
14. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T. Clin Microbiol Infect; 2010 Aug 15; 16(8):1274-81. PubMed ID: 20670293 [Abstract] [Full Text] [Related]
16. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, Thorne GM, Luperchio SA, Arbeit RD, Alder J. Clin Infect Dis; 2008 Apr 15; 46(8):1142-51. PubMed ID: 18444848 [Abstract] [Full Text] [Related]
18. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA. Clin Ther; 2008 Feb 15; 30(2):358-71. PubMed ID: 18343274 [Abstract] [Full Text] [Related]
20. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ. Pediatr Infect Dis J; 2007 Oct 15; 26(10):868-78. PubMed ID: 17901791 [Abstract] [Full Text] [Related] Page: [Next] [New Search]